LICENSES PRODUCTS ACQUIRED (Details) - D F D Agreement $ in Millions |
3 Months Ended | 6 Months Ended | |||||
|---|---|---|---|---|---|---|---|
|
Jun. 29, 2022
USD ($)
|
Nov. 16, 2021
shares
|
Jun. 29, 2021
USD ($)
|
Jun. 30, 2022
USD ($)
|
Jun. 30, 2022
USD ($)
item
|
Dec. 31, 2021
USD ($)
|
Jul. 29, 2020
USD ($)
|
|
| Licenses acquired | |||||||
| Amount payable | $ 10.0 | ||||||
| Amount payable to fund clinical trials | $ 24.0 | ||||||
| Value of shares to be issued | $ 5.0 | ||||||
| Cash payment | $ 0.8 | $ 3.3 | |||||
| Accutane | |||||||
| Licenses acquired | |||||||
| Threshold additional contingent regulatory and commercial milestone payments payable | $ 2.0 | ||||||
| Contingent Payment Derivative | |||||||
| Licenses acquired | |||||||
| Unregistered shares issued | shares | 545,131 | ||||||
| Number of payments | item | 1 | ||||||
| Minimum | |||||||
| Licenses acquired | |||||||
| Percentage of royalties payable on net sales | 0.10% | ||||||
| Maximum | |||||||
| Licenses acquired | |||||||
| Threshold additional contingent regulatory and commercial milestone payments payable | $ 158.0 | ||||||
| Percentage of royalties payable on net sales | 0.20% |
| X | ||||||||||
- Definition Amount payable to fund the clinical trials under the license, collaboration, and assignment agreement. No definition available.
|
| X | ||||||||||
- Definition The cash payment for contingent consideration. No definition available.
|
| X | ||||||||||
- Definition Number of payments to be made on contingent consideration in license, collaboration and assignment agreement. No definition available.
|
| X | ||||||||||
- Definition The value of shares to be issued for payment of contingent consideration. No definition available.
|
| X | ||||||||||
- Definition The percentage of royalties payable on net sales under the license, collaboration, and assignment agreement. No definition available.
|
| X | ||||||||||
- Definition Threshold additional contingent regulatory and commercial milestone payments payable under the license, collaboration, and assignment agreement. No definition available.
|
| X | ||||||||||
- Definition Total amount payable under the license, collaboration, and assignment agreement. No definition available.
|
| X | ||||||||||
- Definition Total number of unregistered common shares of an entity that have been sold or granted to shareholders. No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|